Visterra Inc.










Specialité Stade Position Conseil d’administration
Maladies infectieuses Émergent Co-Investor Observer
Last update: 21/04/2016


Visterra is a clinical-stage biopharmaceutical company that uses its novel Hierotope™ platform to identify unique disease targets and to design and engineer innovative antibody-based therapies intended to be effective as a single-dose administration. Visterra’s technology enables the design and engineering of product candidates which target a specific region of an antigen, or Hierotope, on a pathogen that is common across all strains of the pathogen and is resistant to mutation. The company believes these Hierotopes are critical to the structural and functional integrity of the pathogen, making them highly attractive therapeutic targets. The company is currently focused on developing therapeutics for infectious diseases and its lead product candidate, VIS410, is a human monoclonal antibody being developed for the treatment of hospitalized patients with influenza A, regardless of viral strain. The company’s second product candidate, VIS513, is a human monoclonal antibody for the treatment of dengue that has been shown in preclinical studies to be effective against all four serotypes of the dengue virus. Visterra was founded on the research into the fundamentals of viral evolution and epitope characterization by our scientific founder, Dr. Ram Sasisekharan at MIT.

Contact Visterra :

Media contact: Kathryn Morris

The Yates Network

Tel: 845-635-9828